Role of CCL5 in invasion, proliferation and proportion of CD44+/CD24− phenotype of MCF-7 cells and correlation of CCL5 and CCR5 expression with breast cancer progression
Open accessAbstract
This study was undertaken to observe the effects and possible mechanism of CC chemokine ligand 5 (CCL5) on invasion, proliferation and percentage of CD44+/CD24- subpopulation of human breast cancer line MCF-7 and to investigate the correlation of expression levels of CCL5 and its receptors with the progression of breast cancer. We used real-time RT-PCR to detect the expression levels of CCL5 and its receptors CCR5, CCR1 and CCR3 in 36 breast cancer specimens of different TNM stage and their corresponding normal breast tissue. CCL5 expression and invasive ability of four human breast cancer cell lines MCF-7, SK-BR-3, T-47D and MDA-MB-231 were analyzed by real-time RT-PCR and cell invasion assay, respectively. Effects of recombinant human CCL5 (rhCCL5) on cell proliferation and percentage of the CD44+/CD24- subpopulation in MCF-7 cells were analyzed respectively by MTT assay and flow cytometry. We also used cell invasion assay to detect the invasive ability of both CD44+/CD24- and CD44+/CD24+ subpopulations of MCF-7 cells treated with rhCCL5 and/or CCR5 monoclonal antibody. Our results revealed that CCL5 and CCR5 expression were higher in breast cancer tissue than those in their corresponding normal tissue and breast cancer tissue with higher TNM stage contained more CCL5 mRNA. In addition, CCR5 expression and invasive ability of CD44+/CD24- subpopulation were higher than those of CD44+/CD24+ subpopulation of MCF-7 cells. Moreover, treatment of rhCCL5 increased the proportion of CD44+/CD24- cells and the proliferation of MCF-7 cells. Induction of rhCCL5 increased the cell invasive ability of both CD44+/CD24- and CD44+/CD24+ cells, which could be partially antagonized by CCR5 monoclonal antibody. Collectively, our data show that CCL5 increased the proportion of CD44+/CD24- subpopulation and induced invasion and proliferation of MCF-7 cells, and expression of CCL5 and CCR5 in breast cancer tissue was positively correlated with breast cancer progression.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CCL5, also called RANTES, is another MSC-secreted pro-metastasis cytokine that can be secreted upon interaction with cancer cells and is associated with tumor progression and invasion in various cancers.
“Another MSC-secreted pro-metastasis cytokine, CCL5 (RANTES), can be secreted upon interaction with cancer cells and is associated with tumor progression and invasion in various cancers [73, 87, 100, 142–144].”
From Mesenchymal stem cell secretome and regenerative therapy after cancer (2013) · cites this paper as [144]
The Discussion reports that CCL5 is a promalignant factor in several cancers, and the Introduction reports increased invasion of MCF-7 breast cancer cells after CCL5 treatment. Our copy does not establish that mesenchymal stem cells secrete CCL5 upon interaction with cancer cells; it studies CCL5’s effects and its expression in breast cancer tissue. (LLM, conf=0.88)
Experimental — accuracy not yet measuredCCL5 can be secreted by both bone marrow-derived MSC and adipose-derived stem/stromal cells, and it has pro-proliferative effects on breast cancer cell lines.
“CCL5 can be secreted by both BM-MSC and ASC [100, 144] and displays pro-proliferative activities on breast cancer cell lines [145, 146].”
From Mesenchymal stem cell secretome and regenerative therapy after cancer (2013) · cites this paper as [144]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 35 · Cited by 84
- Authors
- Sun
- Affiliations
- Renmin Hospital of Wuhan University (CN)
- Corresponding author
- Sun
- Venue
- Oncology Reports
- Publisher
- Spandidos Publications
- Published
- 2009-03-16
- Volume
- 21
- Issue
- 4
- Pages
- 1113-21
- ISSN
- 1021-335X (ISSN-L)
- OpenAlex
- W2164291399
- Cited by
- 84
- References
- 35
- Citations by year
- 2024: 3 · 2023: 3 · 2022: 3 · 2021: 1 · 2020: 3 · 2019: 2 · 2018: 9 · 2017: 10 · 2016: 7 · 2015: 6 · 2014: 5 · 2013: 14 · 2012: 4
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Oncology Reports (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Natural Science Foundation of Hubei Province
- Topics
- Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Keywords
- RANTES, CCR5, breast cancer progression, tumor invasion, cell proliferation, MCF-7 cells, chemokine receptors, CCR1, CCR3, TNM stage
- MeSH terms
- Adult, Aged, Antibodies, Monoclonal, Breast, Breast Neoplasms, Female, Humans, Middle Aged, Neoplasm Invasiveness, Neoplasm Staging, Phenotype, Chemokine CCL5, Hyaluronan Receptors, Receptors, CCR5, Cell Line, Tumor, Cell Proliferation, CD24 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
